BACKGROUND: The effect of temporal changes in cancer therapy on health status among childhood cancer survivors has not been evaluated. OBJECTIVE: To compare proportions of self-reported adverse health status outcomes among childhood cancer survivors across 3 decades. DESIGN: Cross-sectional. (ClinicalTrials.gov: NCT01120353). SETTING: 27 North American institutions. PARTICIPANTS: 14 566 adults, who survived for 5 or more years after initial diagnosis (median age, 27 years; range, 18 to 48 years), treated from 1970 to 1999. MEASUREMENTS: Patient report of poor general or mental health, functional impairment, activity limitation, or cancer-related anxiety or pain was evaluated as a function of treatment decade, cancer treatment exposure, chronic health conditions, demographic characteristics, and health habits. RESULTS: Despite reductions in late mortality and the proportions of survivors with severe, disabling, or life-threatening chronic health conditions (33.4% among those treated from 1970 to 1979 and 21.0% among those treated from 1990 to 1999), those reporting adverse health status did not decrease by treatment decade. Compared with survivors diagnosed in 1970 to 1979, those diagnosed in 1990 to 1999 were more likely to report poor general health (11.2% vs. 13.7%; P < 0.001) and cancer-related anxiety (13.3% vs. 15.0%; P < 0.001). From 1970 to 1979 and 1990 to 1999, the proportions of survivors reporting adverse outcomes were higher (P < 0.001) among those with leukemia (poor general health, 9.5% and 13.9%) and osteosarcoma (pain, 23.9% and 36.6%). Temporal changes in treatment exposures were not associated with changes in the proportions of survivors reporting adverse health status. Smoking, not meeting physical activity guidelines, and being either underweight or obese were associated with poor health status. LIMITATION: Considerable improvement in survival among children diagnosed with cancer in the 1990s compared with those diagnosed in the 1970s makes it difficult to definitively determine the effect of risk factors on later self-reported health status without considering their effect on mortality. CONCLUSION: Because survival rates after a diagnosis of childhood cancer have improved substantially over the past 30 years, the population of survivors now includes those who would have died in earlier decades. Self-reported health status among survivors has not improved despite evolution of treatment designed to reduce toxicities. PRIMARY FUNDING SOURCE: The National Cancer Institute.
BACKGROUND: The effect of temporal changes in cancer therapy on health status among childhood cancer survivors has not been evaluated. OBJECTIVE: To compare proportions of self-reported adverse health status outcomes among childhood cancer survivors across 3 decades. DESIGN: Cross-sectional. (ClinicalTrials.gov: NCT01120353). SETTING: 27 North American institutions. PARTICIPANTS: 14 566 adults, who survived for 5 or more years after initial diagnosis (median age, 27 years; range, 18 to 48 years), treated from 1970 to 1999. MEASUREMENTS: Patient report of poor general or mental health, functional impairment, activity limitation, or cancer-related anxiety or pain was evaluated as a function of treatment decade, cancer treatment exposure, chronic health conditions, demographic characteristics, and health habits. RESULTS: Despite reductions in late mortality and the proportions of survivors with severe, disabling, or life-threatening chronic health conditions (33.4% among those treated from 1970 to 1979 and 21.0% among those treated from 1990 to 1999), those reporting adverse health status did not decrease by treatment decade. Compared with survivors diagnosed in 1970 to 1979, those diagnosed in 1990 to 1999 were more likely to report poor general health (11.2% vs. 13.7%; P < 0.001) and cancer-related anxiety (13.3% vs. 15.0%; P < 0.001). From 1970 to 1979 and 1990 to 1999, the proportions of survivors reporting adverse outcomes were higher (P < 0.001) among those with leukemia (poor general health, 9.5% and 13.9%) and osteosarcoma (pain, 23.9% and 36.6%). Temporal changes in treatment exposures were not associated with changes in the proportions of survivors reporting adverse health status. Smoking, not meeting physical activity guidelines, and being either underweight or obese were associated with poor health status. LIMITATION: Considerable improvement in survival among children diagnosed with cancer in the 1990s compared with those diagnosed in the 1970s makes it difficult to definitively determine the effect of risk factors on later self-reported health status without considering their effect on mortality. CONCLUSION: Because survival rates after a diagnosis of childhood cancer have improved substantially over the past 30 years, the population of survivors now includes those who would have died in earlier decades. Self-reported health status among survivors has not improved despite evolution of treatment designed to reduce toxicities. PRIMARY FUNDING SOURCE: The National Cancer Institute.
Authors: Irma W E M van Dijk; Mathilde C Cardous-Ubbink; Helena J H van der Pal; Richard C Heinen; Flora E van Leeuwen; Foppe Oldenburger; Rob M van Os; Cécile M Ronckers; Antoinette Y N Schouten-van Meeteren; Huib N Caron; Caro C E Koning; Leontien C M Kremer Journal: Int J Radiat Oncol Biol Phys Date: 2012-09-03 Impact factor: 7.038
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green Journal: Pediatr Blood Cancer Date: 2011-10-28 Impact factor: 3.167
Authors: Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04 Impact factor: 4.254
Authors: Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2013-08-12 Impact factor: 3.167
Authors: Stefan Essig; Qiaozhi Li; Yan Chen; Johann Hitzler; Wendy Leisenring; Mark Greenberg; Charles Sklar; Melissa M Hudson; Gregory T Armstrong; Kevin R Krull; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Claudia E Kuehni; Yutaka Yasui; Paul C Nathan Journal: Lancet Oncol Date: 2014-06-19 Impact factor: 41.316
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Daniel J Zheng; Kevin R Krull; Yan Chen; Lisa Diller; Yutaka Yasui; Wendy Leisenring; Pim Brouwers; Rebecca Howell; Jin-Shei Lai; Lyn Balsamo; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Nina S Kadan-Lottick Journal: Cancer Date: 2018-06-11 Impact factor: 6.860
Authors: Todd M Gibson; Sogol Mostoufi-Moab; Kayla L Stratton; Wendy M Leisenring; Dana Barnea; Eric J Chow; Sarah S Donaldson; Rebecca M Howell; Melissa M Hudson; Anita Mahajan; Paul C Nathan; Kirsten K Ness; Charles A Sklar; Emily S Tonorezos; Christopher B Weldon; Elizabeth M Wells; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger Journal: Lancet Oncol Date: 2018-11-08 Impact factor: 41.316
Authors: Carmen L Wilson; Carrie R Howell; Robyn E Partin; Lu Lu; Sue C Kaste; Daniel A Mulrooney; Ching-Hon Pui; Jennifer Q Lanctot; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2018-07-29 Impact factor: 3.167
Authors: Tara M Brinkman; Christopher J Recklitis; Gisela Michel; Martha A Grootenhuis; James L Klosky Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan Journal: Semin Oncol Date: 2020-03-04 Impact factor: 4.929
Authors: Adam P Yan; Yan Chen; Tara O Henderson; Kevin C Oeffinger; Melissa M Hudson; Todd M Gibson; Joseph P Neglia; Wendy M Leisenring; Kirsten K Ness; Jennifer S Ford; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui; Paul C Nathan Journal: J Clin Oncol Date: 2020-03-06 Impact factor: 44.544
Authors: Jessica M Scott; Nan Li; Qi Liu; Yutaka Yasui; Wendy Leisenring; Paul C Nathan; Todd Gibson; Saro H Armenian; Tormod S Nilsen; Kevin C Oeffinger; Kirsten K Ness; Scott C Adams; Leslie L Robison; Gregory T Armstrong; Lee W Jones Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Fiona S M Schulte; Michaela Patton; Nicole M Alberts; Alicia Kunin-Batson; Barbara A Olson-Bullis; Caitlin Forbes; K Brooke Russell; Alexandra Neville; Lauren C Heathcote; Cynthia W Karlson; Nicole M Racine; Courtney Charnock; Matthew C Hocking; Pia Banerjee; Perri R Tutelman; Melanie Noel; Kevin R Krull Journal: Cancer Date: 2020-10-28 Impact factor: 6.860